Skip to main content

USO DE LA SECUENCIACION DE NUEVA GENERACION (NGS) COMO UNICA HERRAMIENTA GENOMICA PARA LA MEJORA DEL DIAGNOSTICO EL PRONOSTICO Y EL TRATAMIENTO DE PACIENTES ADULTOS CON LEUCEMIA LINFOBLASTICA DE TIPO T (LLT)

PI19/01828

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION CONTRA LA LEUCEMIA JOSEP CARRERAS
Execution centre FUNDACION INSTITUTO DE INVESTIGACION CONTRA LA LEUCEMIA JOSEP CARRERAS

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication

Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials

  • González Gil, Celia|||0000-0002-7582-1482
  • Morgades, Mireia|||0000-0003-0295-2534
  • Lopes, Thaysa|||0000-0003-1522-6312
  • Fuster-Tormo, Francisco|||0000-0002-1220-6183
  • Montesinos, Pau|||0000-0002-3275-5593
  • Barba, Pere|||0000-0001-7076-7969
  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Hermosín, Lourdes
  • Maluquer, Clara
  • González Campos, José
  • Bernal, Teresa|||0000-0002-2338-513X
  • Arriaga, Marta Sitges
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Martino Bofarull, Rodrigo|||0000-0001-5143-4042
  • Larrayoz, María José
  • Artola, Teresa
  • Torrent Catarineu, Anna|||0000-0002-3727-5716
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Tormo, Mar|||0000-0001-9622-1649
  • Gil, Cristina
  • Novo, Andrés
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Queipo, María-Paz
  • González-Martínez, Teresa
  • Cabrero, Mónica
  • Cladera, Antonia
  • Cervera, José|||0000-0001-8252-1106
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Genescà, Eulàlia|||0000-0002-5657-4842
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia: Long-term results

  • Ribera, Josep-Maria
  • Morgades, Mireia
  • Ribera, Jordi
  • Montesinos, Pau
  • Cano-Ferri, Isabel
  • López Martínez, Pilar
  • Esteve, Jordi
  • Esteban, Daniel
  • García-Fortes, María
  • Alonso, Natalia
  • González-Campos, José
  • Bermúdez, Arancha
  • Torrent, Anna
  • Genescà, Eulàlia
  • Maluquer, Clara
  • Martínez-López, Joaquín
  • García-Sanz, Ramón
This project was supported in part by the ISCIII (PI14/01971 and PI19/01828), co-funded by ERDF/ESF, “A way to make Europe”/“Investing in your future,” CERCA/Generalitat de Catalunya SGR 2017 288 (GRC)/“La Caixa.” This project has also been supported by Incyte Biosciences International S.a.r.l. with study medication and financial support. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116026. This Joint Undertaking receives support from the “European Union's Horizon 2020 research and innovation and EFPIA.”, Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • García-Calduch, Olga
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Montesinos, Pau|||0000-0002-3275-5593
  • Cano-Ferri, Isabel
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Esteban Corredera, Daniel|||0000-0001-8897-3170
  • García Fortes, María|||0000-0002-0959-9449
  • Alonso Vence, Natalia
  • González Campos, José
  • Bermúdez, Arancha
  • Torrent Catarineu, Anna|||0000-0002-3727-5716
  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Martínez-Lopez, Joaquín
  • García-Sanz, Ramón|||0000-0003-4120-2787
Promising results have been shown with the combination of ponatinib and chemotherapy in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL). The PONALFIL (Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia) trial combined ponatinib (30 mg/d) with standard induction and consolidation chemotherapy followed by allogeneic hematopoietic stem cell transplant (alloHSCT) in newly diagnosed Ph + ALL patients aged 18 to 60 years. Ponatinib was only given pre-emptively after alloHSCT. Primary end points were hematologic and molecular response before alloHSCT and event-free survival (EFS), including molecular relapse as event. Thirty patients (median age, 49 years; range, 19-59 years) entered the trial. All exhibited hematologic response, and alloHSCT was performed in 26 patients (20 in complete molecular response and 6 in major molecular response). Only 1 patient died (of graft-versus-host disease), and 5 patients exhibited molecular relapse after alloHSCT. No tyrosine kinase inhibitor was given after HSCT in 18 of 26 patients. Twenty-nine patients are alive (median follow-up, 2.1 years; range, 0.2-4.0 years), with 3-year EFS and overall survival (OS) of 70% (95% confidence interval, 51-89) and 96% (95% confidence interval, 89-100), respectively. Comparison of the PONALFIL and the ALLPh08 (Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph [BCR-ABL] Positive; same schedule, using imatinib as the tyrosine kinase inhibitor) trials by propensity score showed significant improvement in OS for patients in PONALFIL (3-year OS, 96% vs 53%; P =.002). The most frequent grade 3 to 4 adverse events were hematologic (42%), infectious (17%), and hepatic (22%), with only one vascular occlusive event. The combination of chemotherapy with ponatinib followed by alloHSCT is well tolerated, with encouraging EFS in adults with newly diagnosed Ph + ALL. Cross-trial comparison suggests improvement vs imatinib (clinicaltrials.gov identifier #NCT02776605).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)

  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Morgades, Mireia|||0000-0003-0295-2534
  • González Gil, Celia|||0000-0002-7582-1482
  • Fuster-Tormo, Francisco|||0000-0002-1220-6183
  • Haferlach, Claudia
  • Meggendorfer, Manja
  • Montesinos, Pau|||0000-0002-3275-5593
  • Barba, Pere|||0000-0001-7076-7969
  • Gil, Cristina
  • Coll, Rosa|||0000-0003-0560-1254
  • Moreno, Maria José
  • Martínez-Carballeira, Daniel|||0000-0003-4840-7822
  • García Cadenas, Irene|||0000-0002-2994-9055
  • Vives Polo, Susana|||0000-0003-2217-5285
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • González Campos, José
  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Mercadal, Santiago|||0000-0003-4741-7885
  • Artola, Maria Teresa
  • Cladera, Antonia
  • Tormo, Mar|||0000-0001-9622-1649
  • Bermúdez, Arancha
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Amigo, María-Luz|||0000-0002-3356-9290
  • Monsalvo, Silvia
  • Novo, Andrés
  • Cervera, Marta
  • Garcia-Guiñon, Antonio|||0000-0003-0006-4162
  • Ciudad Pizarro, Juana
  • Cervera, José|||0000-0001-8252-1106
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • Granada, Isabel|||0000-0002-4275-0104
  • Haferlach, T.|||0000-0003-0196-2837
  • Orfao, Alberto|||0000-0002-0007-7230
  • Sole, F.|||0000-0002-3251-2161
  • Ribera, Jose-Maria|||0000-0003-1042-6024
The potential prognostic value of conventional karyotyping in adult T-cell acute lymphoblastic leukemia (T-ALL) remains an open question. We hypothesized that a modified cytogenetic classification, based on the number and type of cytogenetic abnormalities, would allow the identification of high-risk adult T-ALL patients. Complex karyotype defined by the presence of ≥3 cytogenetic alterations identified T-ALL patients with poor prognosis in this study. Karyotypes with ≥3 abnormalities accounted for 16 % (22/139) of all evaluable karyotypes, corresponding to the largest poor prognosis cytogenetic subgroup of T-ALL identified so far. Patients carrying karyotypes with ≥3 cytogenetic alterations showed a significantly inferior response to therapy, and a poor outcome in terms of event-free survival (EFS), overall survival (OS) and cumulative incidence of relapse (CIR), independently of other baseline characteristics and the end-induction minimal residual disease (MRD) level. Additional molecular analyses of patients carrying ≥3 cytogenetic alterations showed a unique molecular profile that could contribute to understand the underlying molecular mechanisms of resistance and to evaluate novel targeted therapies (e.g. IL7R directed) with potential impact on outcome of adult T-ALL patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Latest Contributions of Genomics to T-Cell Acute Lymphoblastic Leukemia (T-ALL)

  • Genescà, Eulàlia|||0000-0002-5657-4842
  • González Gil, Celia|||0000-0002-7582-1482
As for many neoplasms, initial genetic data about T-cell acute lymphoblastic leukemia (T-ALL) came from the application of cytogenetics. This information helped identify some recurrent chromosomal alterations in T-ALL at the time of diagnosis, although it was difficult to determine their prognostic impact because of their low incidence in the specific T-ALL cohort analyzed. Genetic knowledge accumulated rapidly following the application of genomic techniques, drawing attention to the importance of using high-resolution genetic techniques to detect cryptic aberrations present in T-ALL, which are not usually detected by cytogenetics. We now have a clearer apprecia-tion of the genetic landscape of the different T-ALL subtypes at diagnosis, explaining the particular oncogenetic processes taking place in each T-ALL, and we have begun to understand relapse-spe-cific mechanisms. This review aims to summarize the latest advances in our knowledge of the genome in T-ALL. We highlight areas where the research in this subtype of ALL is progressing with the aim of identifying key questions that need to be answered in the medium-long term if this knowledge is to be applied in clinics.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Early T-Cell Precursor ALL and Beyond, Immature and Ambiguous Lineage T-ALL Subsets

  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Starza, Roberta la|||0000-0001-5854-9846
A wide range of immature acute leukemias (AL), ranging from acute myeloid leukemias with minimal differentiation to acute leukemias with an ambiguous lineage, i.e., acute undifferentiated leukemias and mixed phenotype acute leukemia with T-or B-plus myeloid markers, cannot be definitely assigned to a single cell lineage. This somewhat "grey zone" of AL expresses partly overlapping features with the most immature forms of T-cell acute lymphoblastic leukemia (T-ALL), i.e., early T-cell precursor ALL (ETP-ALL), near-ETP-ALL, and pro-T ALL. These are troublesome cases in terms of precise diagnosis because of their similarities and overlapping phenotypic features. Moreover, it has become evident that they share several genomic alterations, raising the question of how their phenotypes reflect distinct AL entities. The aim of this review was to provide a systematic overview of the genetic events associated with immature T-ALL and outline their relationship with treatment choices and outcomes, especially looking at the most recent preclinical and clinical studies. We wish to offer a basis for using the genetic information for new diagnostic algorithms, in order to better stratify patients and improve their management with more efficient and personalized therapeutic options. Understanding the genetic profile of this high-risk T-ALL subset is a prerequisite for changing the current clinical scenario.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genomics improves risk stratification of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials

  • González Gil, Celia|||0000-0002-7582-1482
  • Morgades, Mireia|||0000-0003-0295-2534
  • Lopes, Thaysa|||0000-0003-1522-6312
  • Fuster-Tormo, Francisco|||0000-0002-1220-6183
  • García-Chica, Jesús
  • Zhao, Ran
  • Montesinos, Pau|||0000-0002-3275-5593
  • Torrent Catarineu, Anna|||0000-0002-3727-5716
  • Díaz-Beyá, Marina|||0000-0001-9624-2597
  • Coll, Rosa|||0000-0003-0560-1254
  • Hermosín, Lourdes
  • Mercadal, Santiago|||0000-0003-4741-7885
  • González Campos, José
  • Zamora, Lurdes|||0000-0003-1713-7110
  • Artola, Teresa
  • Vall-Llovera, Ferran|||0000-0002-0718-5955
  • Tormo, Mar|||0000-0001-9622-1649
  • Gil, Cristina
  • Barba, Pere|||0000-0001-7076-7969
  • Novo, Andrés
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Bernal, Teresa|||0000-0002-2338-513X
  • de Ugarriza, Paula López
  • Queipo, María-Paz
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Giménez, Alicia
  • González-Martínez, Teresa
  • Cladera, Antonia
  • Cervera, José|||0000-0001-8252-1106
  • Fernández-Martín, Rosa
  • Ardaiz, María Ángeles
  • Vidal, María Jesús
  • Baena, Ángela
  • Lopez-Bigas, Nuria|||0000-0003-4925-8988
  • Bigas Salvans, Anna|||0000-0003-4801-6899
  • Maciejewski, Jaroslaw|||0000-0002-6837-4346
  • Orfao, Alberto|||0000-0002-0007-7230
  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Genescà, Eulàlia|||0000-0002-5657-4842
Genetic information has been crucial to understand the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) at diagnosis and at relapse, but still nowadays has a limited value in a clinical context. Few genetic markers are associated with the outcome of T-ALL patients, independently of measurable residual disease (MRD) status after therapy. In addition, the prognostic relevance of genetic features may be modulated by the specific treatment used. We analyzed the genetic profile of 145 T-ALL patients by targeted deep sequencing. Genomic information was integrated with the clinical-biological and survival data of a subset of 116 adult patients enrolled in two consecutive MRD-oriented trials of the Spanish PETHEMA (Programa Español de Tratamientos en Hematología) group. Genetic analysis revealed a mutational profile defined by DNMT3A/ N/KRAS/ MSH2/ U2AF1 gene mutations that identified refractory/resistant patients. Mutations in the DMNT3A gene were also found in the non-leukemic cell fraction of patients with T-ALL, revealing a possible mutational-driven clonal hematopoiesis event to prime T-ALL in elderly. The prognostic impact of this adverse genetic profile was independent of MRD status on day +35 of induction therapy. The combined worse-outcome genetic signature and MRD on day +35 allowed risk stratification of T-ALL into standard or high-risk groups with significantly different 5-year overall survival (OS) of 52% (95% confidence interval: 37-67) and 17% (95% confidence interval: 1-33), respectively. These results confirm the relevance of the tumor genetic profile in predicting patient outcome in adult T-ALL and highlight the need for novel gene-targeted chemotherapeutic schedules to improve the OS of poor-prognosis T-ALL patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Ponalfil trial for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia, Long-term results

  • Ribera, Jose-Maria|||0000-0003-1042-6024
  • Morgades, Mireia|||0000-0003-0295-2534
  • Ribera Salas, Jordi|||0000-0003-4796-6470
  • Montesinos, Pau|||0000-0002-3275-5593
  • Cano-Ferri, Isabel
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Esteve Reyner, Jordi|||0000-0002-8056-648X
  • Esteban Corredera, Daniel|||0000-0001-8897-3170
  • García Fortes, María|||0000-0002-0959-9449
  • Alonso, Natalia
  • González Campos, José
  • Bermúdez, Arancha
  • Torrent Catarineu, Anna|||0000-0002-3727-5716
  • Genescà, Eulàlia|||0000-0002-5657-4842
  • Maluquer, Clara
  • Martínez-López, José
  • García-Sanz, Ramón|||0000-0003-4120-2787